Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.76 -0.59 (-1.82%)
Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
News headline image
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors. 
Via The Motley Fool
Topics Stocks
News headline image
US-India Trade War Escalates: New Tariffs Spark Inflation Fears and Corporate Profit Warnings
The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these... 
Via MarketMinute
Topics Economy Government Supply Chain
News headline image
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda ↗
Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy. 
Via Benzinga
News headline image
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk ↗
Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs. 
Via Investor's Business Daily
News headline image
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters ↗
Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
How Is The Market Feeling About Teva Pharmaceutical Indus? ↗
 
Via Benzinga
News headline image
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy ↗
Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations. 
Via Benzinga
Topics Earnings
News headline image
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings ↗
Teva stock is trading below key levels. 
Via Investor's Business Daily
News headline image
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong ↗
Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition. 
Via Benzinga
News headline image
A Glimpse of Teva Pharmaceutical Indus's Earnings Potential ↗
 
Via Benzinga
News headline image
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters ↗
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Looking Into Teva Pharmaceutical Indus's Recent Short Interest ↗
 
Via Benzinga
News headline image
Teva Releases Q2 2025 Aide Memoire
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
What Analysts Are Saying About Teva Pharmaceutical Indus Stock ↗
 
Via Benzinga
News headline image
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys? ↗
Via The Motley Fool
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.